ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Protocol ID
AOST2032
Disease (Sub Disease)
High Grade Osteosarcoma
Localized Osteosarcoma
Metastatic Osteosarcoma
Secondary Osteosarcoma
Diagnosis Stage
Newly diagnosed
Location
VIC
Sponsor
National Cancer Institute (NCI)
Links
External Registry ≫
Trial Status
Open
Sites
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 2/3
Age Eligibility
up to 40 Years
International registry ID's
NCT05691478
Back to Registry
Study Title AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Protocol ID AOST2032
Disease (Sub Disease) High Grade Osteosarcoma
Localized Osteosarcoma
Metastatic Osteosarcoma
Secondary Osteosarcoma
Diagnosis Stage Newly diagnosed
Location VIC
Sponsor National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT05691478
Trial Status Open
Sites Royal Children's Hospital
Study Type Treatment
Phase Phase 2/3
Age Eligibility up to 40 Years
International registry ID's NCT05691478

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.